Browsing Tag
CD47
3 posts
ALX Oncology turns to biomarker-led development after evorpacept gastric cancer results
ALX Oncology’s evorpacept shows stronger activity in CD47-high HER2 tumors as the company seeks partners and prioritizes breast cancer.
How ALX Oncology Holdings Inc is repositioning its clinical strategy to achieve pivotal trial readiness by end-2026
ALX Oncology outlines its 2026 pivotal trial roadmap as ASPEN-09 expands and $150m funding extends runway. Read what changes next.
Why predictive biomarkers may determine ALX Oncology’s competitive viability in HER2-positive breast cancer
Find out why CD47 biomarkers could determine ALX Oncology’s ability to compete in HER2-positive breast cancer and what risks remain for evorpacept.